- Ongoing management with semi-annual reviews
- Chronic condition requiring lifelong monitoring
- 85%
China versus the U.S.
- China clinical rate
- $600 – $5,000
- $2,800
- United States
- $8,000 – $30,000
- $19,000
- You save
- ~85%
- $16,200 per procedure
Prices are approximate ranges. Actual cost depends on hospital, surgeon, materials, and case complexity.
What the procedure involves.
Comprehensive management program for autosomal dominant polycystic kidney disease (ADPKD) at specialized nephrology centers in China. Programs include genetic counseling, tolvaptan therapy initiation, cyst complication management, and long-term disease monitoring. China's large PKD patient population has driven expertise in both medical and surgical management approaches.
Step by step.
Comprehensive PKD Assessment
MRI volumetry, GFR measurement, genetic testing, and total kidney volume calculation for prognostication
Risk Classification
Mayo classification staging to determine disease progression rate and treatment eligibility
Therapy Initiation
Tolvaptan initiation with liver function monitoring, blood pressure optimization, and lifestyle counseling
Long-Term Monitoring
Regular imaging, renal function tracking, complication management, and family screening coordination
- Access to tolvaptan at significantly reduced cost
- Expert PKD specialists with large case volumes
- Comprehensive genetic counseling services
- Integrated management of hepatic and renal cysts
- Tolvaptan-associated liver toxicity requiring monitoring
- Polyuria and thirst from vasopressin antagonism
- Disease progression despite treatment
- Need for eventual renal replacement therapy
Ask the AI for hospitals that handle polycystic kidney disease management.
Prices shown are approximate ranges for reference only. Actual costs vary by hospital, complexity, and individual patient needs. Always consult with healthcare professionals for medical decisions.